Skip to main content
. 2024 Feb 28;271(5):2810–2823. doi: 10.1007/s00415-024-12236-0

Fig. 1.

Fig. 1

Patient disposition. aTwo patients who withdrew from PROPEL for logistical reasons not related to the efficacy or safety of cipa + mig (one due to an AE of COVID-19-related pneumonia and one because of concerns about travelling to the study site due to COVID-19) were enrolled in the OLE. AE adverse event; ERT enzyme replacement therapy; OLE open-label extension; OLE-ES open-label extension enrolled subjects